Regenerx Overview
- Year Founded
-
1982
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
RGRX
- Investments
-
1
Regenerx General Information
Description
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Contact Information
Website
www.regenerx.comCorporate Office
- 15245 Shady Grove Road
- Suite 470
- Rockville, MD 20850
- United States
Corporate Office
- 15245 Shady Grove Road
- Suite 470
- Rockville, MD 20850
- United States
Regenerx Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 457.00 |
Regenerx Financials Summary
As of 31-Mar-2023, Regenerx has a trailing 12-month revenue of $76.8K.
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 15,983 | 20,849 | 22,561 | 60,190 |
| Revenue | 77 | 77 | 77 | 77 |
| EBITDA | (1,363) | (1,402) | (1,273) | (1,295) |
| Net Income | (1,689) | (1,727) | (1,598) | (1,523) |
| Total Assets | 187 | 382 | 1,285 | 552 |
| Total Debt | 1,495 | 1,446 | 1,165 | 1,026 |
Regenerx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Regenerx Comparisons
Industry
Financing
Details
Regenerx Competitors (24)
One of Regenerx’s 24 competitors is viDA Therapeutics, a Venture Capital-Backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| viDA Therapeutics | Venture Capital-Backed | Vancouver, Canada | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Regenerx Patents
Regenerx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3177764-A1 | Beta thymosin peptides for treating viral infections | Pending | 05-May-2020 | ||
| EP-4146694-A2 | Beta thymosin peptides for treating viral infections | Inactive | 05-May-2020 | ||
| US-20230190878-A1 | Beta thymosin peptides for treating viral infections | Inactive | 05-May-2020 | ||
| WO-2021225960-A2 | Beta thymosin peptides for treating viral infections | Inactive | 05-May-2020 | ||
| WO-2021225960-A3 | Beta thymosin peptides for treating viral infections | Inactive | 05-May-2020 | A61K38/2292 |
Regenerx Signals
Regenerx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Regenerx Investments (1)
Regenerx’s most recent deal was a Joint Venture with ReGenTree. The deal was made on 01-Jan-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ReGenTree | 01-Jan-2015 | Joint Venture | Drug Discovery |
Regenerx ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Regenerx FAQs
-
When was Regenerx founded?
Regenerx was founded in 1982.
-
Where is Regenerx headquartered?
Regenerx is headquartered in Rockville, MD.
-
What is the size of Regenerx?
Regenerx has 8 total employees.
-
What industry is Regenerx in?
Regenerx’s primary industry is Drug Discovery.
-
Is Regenerx a private or public company?
Regenerx is a Public company.
-
What is Regenerx’s stock symbol?
The ticker symbol for Regenerx is RGRX.
-
What is Regenerx’s current revenue?
The trailing twelve month revenue for Regenerx is $76.8K.
-
Who are Regenerx’s competitors?
viDA Therapeutics, Light Chain Bioscience, Virometix, Lisata Therapeutics, and Sangamo Therapeutics are some of the 24 competitors of Regenerx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process